Brazil's Anvisa approves pediatric schistosomiasis treatment for ages 3 months to 6 years

Brazil's health regulator Anvisa approved a medication for schistosomiasis in children aged 3 months to 6 years, expanding treatment options for a neglected tropical disease. The approval addresses a gap in pediatric dosing, though details on the drug and efficacy data are not provided. This is a public-health advancement for Brazil, where schistosomiasis remains endemic.